MYOACTIVE ARRIVES

ZEISS enters the fight — launched October 1, 2026, in Canada.

The newest contender just walked in. ZEISS launched MyoActive on October 1, 2026, in Canada, built on what the company calls Dynamic Signal Theory and M.O.V.E. technology. It's the third major myopia control lens to reach parents with serious clinical backing — and its headline numbers are strong.

Children wearing MyoActive showed 0.60 diopters less myopia progression than the control group. In practical terms, that's a meaningful difference in how strong a child's prescription becomes — the difference between a mild prescription and a significantly stronger one over the years of eye growth. And adaptation was near-universal: 98 percent of children adapted to the lenses within a week. For parents, that number might matter most. The best lens in the world is useless if a kid won't wear it.

ZEISS is framing MyoActive around dynamic, age-adapted signaling — the lens design accounts for how children's eyes and visual behavior change as they grow. It's a slightly different theoretical angle than its rivals' defocus approaches, and the myopia research community will be watching the long-term data closely.

Canada got the launch. Other markets will follow on their own regulatory timelines — that's how this category works. But the direction is unmistakable: three global optics giants, three clinically backed lenses, one shared conclusion. Childhood myopia is treatable territory now.

*Talk to your eye doctor: MyoActive launched in Canada first — ask about availability timelines in your region and how it compares with the options already on the market.*

"0.60 diopters less progression. 98% adapted in a week. The new kid is legit."